Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Culture

4 Aug 2022

NFL All-Star Aaron Rodgers Says Ayahuasca Helped Him Become MVP

All-star NFL quarterback Aaron Rodgers appeared on the Aubrey Marcus Podcast, sharing that he took ayahuasca prior to his back-to-back MVP seasons....

By Microdose NewsDesk

Industry

3 Aug 2022

Braxia Acquires KetaMD, Enters U.S. Telemedicine Industry

Braxia Scientific Enters U....

By Microdose NewsDesk

Finance

3 Aug 2022

Horizons Psychedelic ETF Performs 1:4 Share Consolidation

Shareholders of the Horizons Psychedelic Stock Index ETF (PSYK) might have noticed a sudden and drastic price change this week....

By Microdose NewsDesk

Finance

2 Aug 2022

Cathie Wood’s ARK Fund Buys Over 3 Million ATAI Shares

In mid-July, we had the ARK fund at a total investment of 621,812 shares for the month....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

28 Jul 2022

Canadian Government Issues First Ever Grant to Study Psilocybin

CAMH receives first Canadian federal (CIHR) grant to study psilocybin....

By Microdose NewsDesk

Breaking News, Industry

28 Jul 2022

Compass Pathways Launches New Phase 2 Trial for Anorexia

Today we have more positive news, with the firm announcing a new Phase 2 trial using its COMP360 psilocybin for anorexia, taking place at prestigious sites like King's College London...

By Microdose NewsDesk

Industry

26 Jul 2022

Small Pharma Granted U.S. Patent for Injectable DMT

Key U....

By Microdose NewsDesk

Industry

26 Jul 2022

Nonprofit B.More Submits Phase 2b Trial for Alcohol Use to the FDA

B....

By Microdose NewsDesk

Industry, Press Releases

25 Jul 2022

Mindbio Research Partners Receive $1.4 M Grant for Microdosing Trial

Blackhawk's Mindbio Therapeutics Announces Research Collaborators at University of Auckland Receive Grant Funding of $1....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.